Dupont vs. Francisco

A petition for revival of an abandoned patent application must be filed strictly within the statutory period of four months from the date of abandonment, which period is non-extendible and not subject to equitable relaxation even where the abandonment resulted from counsel's negligence, because the negligence of a patent applicant's resident agent binds the applicant, and because public interest in access to affordable medicines and protection of third-party rights invested in good faith outweigh the applicant's claim to exclusive monopoly.

E.I. Dupont De Nemours and Company, a Delaware corporation and assignee of inventors of Angiotensin II Receptor Blocking Imidazole (losartan), filed Philippine Patent Application No. 35526 on July 10, 1987, for a hypertension and congestive heart failure medication. The application was prosecuted by resident agent Atty. Nicanor D. Mapili. Following an Office Action mailed on July 19, 1988, the application was deemed abandoned on September 20, 1988, for failure to respond within the prescribed period. Petitioner alleged it discovered the abandonment only on January 30, 2002, and filed a Petition for Revival on May 29, 2002—over thirteen years later—attributing the delay to Atty. Mapili's failure to inform it of the abandonment and his subsequent death.

• The Patent Application: Petitioner E.I. Dupont De Nemours, assignee of inventors Carino, Duncia, and Wong, filed Philippine Patent Application No. 35526 on July 10, 1987, for losartan, an angiotensin II receptor blocker used to treat hypertension and congestive heart failure. The product was marketed by licensee Merck, Sharpe, and Dohme Corporation under the brands Cozaar and Hyzaar.
• Abandonment: The application was assigned to Patent Examiner Precila O. Bulihan on June 7, 1988. An Office Action was mailed to petitioner's resident agent, Atty. Nicanor D. Mapili, on July 19, 1988. When no response was received, the application was declared abandoned on September 20, 1988, pursuant to Section 111(a) of the 1962 Revised Rules of Practice.
• Petitioner's Explanation: Petitioner alleged that Atty. Mapili never informed it of the abandonment or his death, which petitioner discovered only in March 1996 during a senior patent attorney's visit to the Philippines. Petitioner claimed it first had actual notice of the abandonment on January 30, 2002, when the Intellectual Property Office issued Paper No. 2 stating the application had been abandoned.
• Petition for Revival: On May 29, 2002, petitioner filed a Petition for Revival under Section 113 of the 1962 Revised Rules of Practice, arguing that the delay was unavoidable due to counsel's negligence and death. The petition was filed approximately thirteen years after the date of abandonment.
• Therapharma's Intervention: Therapharma, Inc., a local pharmaceutical company, filed a Motion for Leave to Intervene in the Court of Appeals. It alleged that on January 4, 2003, it had filed an application with the Bureau of Food and Drugs for its own losartan product, "Lifezar," which was granted. Therapharma conducted patent searches and found no pending patent applications for losartan. It had invested over P20,000,000.00 in developing its product and had been threatened by Merck with legal action if it continued marketing Lifezar, despite petitioner having no pending patent application at the time.
• Public Interest Considerations: Evidence showed that hypertension affects approximately 12.6 million Filipinos and is a major risk factor for cardiovascular disease. The entry of Therapharma's Lifezar into the market in 2004 caused petitioner's Cozaar prices to drop from P55.00 to P44.00 for the 100mg dosage within one month, and increased losartan unit sales by 44% within five months.

• Substantial Compliance with Rule 45: Petitioner argued that it substantially complied with Rule 45, Section 4 by attaching the Court of Appeals decisions and resolutions, which quoted extensively from the record, and subsequently submitting additional documents in its Consolidated Reply.
• Proper Mode of Appeal: Petitioner maintained that Rule 45 was the proper remedy, not Rule 65, because the Court of Appeals had already resolved both the intervention and the merits of the case, and no plain, speedy remedy existed in the ordinary course of law.
• Nature of Issues: Petitioner argued that the petition raised questions of law regarding the interpretation of Republic Act No. 165 and the applicability of the Rules of Court to intervention in patent appeals, not questions of fact.
• Propriety of Intervention: Petitioner contended that intervention should not have been allowed because patent revival proceedings are ex parte and confidential under Sections 13 and 14 of the 1962 Revised Rules of Practice, and Therapharma had no vested rights since no patent had been granted.
• Excusable Negligence: Petitioner argued that it was not negligent in prosecuting the application; rather, Atty. Mapili or his heirs failed to inform it of crucial developments. As a foreign client without immediate supervision over local counsel, petitioner asserted it should not be bound by counsel's negligence and that the delay was unavoidable.
• Right of Priority: Petitioner claimed protection under the Paris Convention's right of priority, arguing that its July 11, 1986 U.S. patent application removed the invention from the public domain in the Philippines.

• Procedural Defects: Therapharma argued that the petition should be dismissed for failure to attach material portions of the record required by Rule 45, Section 4, and that petitioner should have filed a petition for certiorari under Rule 65 to assail the Court of Appeals' discretionary grant of intervention.
• Inexcusable Negligence: The Intellectual Property Office countered that petitioner was inexcusably negligent, having allowed eight years to pass without requesting a status update. The Office maintained that Section 111(a) of the 1962 Revised Rules clearly stated that abandonment runs from the mailing of the notice, not actual notice, and that the four-month revival period under Section 113 is mandatory and non-extendible.
• Third-Party Rights and Public Interest: Therapharma argued that it possessed vested rights in its product registration and marketing investments made in good faith reliance on the application's abandoned status. It emphasized that revival would prejudice public interest by eliminating competition for a hypertension medication affecting millions of Filipinos, thereby increasing prices.
• Applicability of Schwartz: Respondents cited Schuartz v. Court of Appeals to assert that the negligence of a patent applicant's counsel binds the applicant, and that petitioner's 13-year delay constituted laches.
• Public Domain: Therapharma maintained that a mere patent application does not vest property rights; the invention became part of the public domain when the application was abandoned and not revived within the statutory period.

• Mode of Appeal: Whether petitioner properly availed of a petition for review on certiorari under Rule 45 instead of certiorari under Rule 65.
• Compliance with Rule 45: Whether the petition complied with the documentary requirements of Rule 45, Section 4.
• Nature of Issues: Whether the petition raises questions of law or questions of fact.
• Intervention: Whether the Court of Appeals erred in allowing Therapharma, Inc. to intervene in the appeal.
• Revival Period: Whether the Court of Appeals erred in denying the revival of the patent application on the ground that it was filed beyond the statutory period.
• Negligence of Counsel: Whether Schuartz v. Court of Appeals applies to bind petitioner to the negligence of its resident agent.
• Public Interest: Whether third-party rights and public interest would be prejudiced by the revival of the patent application.
• Right of Priority: Whether petitioner's prior U.S. patent application prevents the invention from becoming part of the public domain.

• Mode of Appeal: Rule 45 was the proper remedy. Once the Court of Appeals resolved the merits of the case together with the intervention, the proper mode of appeal to the Supreme Court is Rule 45, not Rule 65, which is limited to correcting errors of jurisdiction and not errors of judgment.
• Compliance with Rule 45: Substantial compliance with Rule 45, Section 4 was established. Following the Magsino and Galvez guideposts, petitioner attached sufficient documents to support its allegations, and subsequently submitted additional records in its Consolidated Reply, satisfying the requirements of substantial justice.
• Nature of Issues: The petition raises questions of law, specifically the interpretation of Republic Act No. 165 regarding intervention in appeals and the construction of statutory periods for patent revival, which do not require review or evaluation of evidence.
• Intervention: The Court of Appeals did not err in allowing intervention. While the 1962 Revised Rules of Practice govern proceedings before the Intellectual Property Office, once an appeal is taken to the Court of Appeals, the Rules of Court apply. Rule 19 of the Rules of Court grants courts discretion to allow intervention by persons with a legal interest in the matter. Therapharma demonstrated a legal interest: it had invested substantially in its losartan product, conducted patent searches showing no pending applications, and faced actual threats of legal action from petitioner's licensee despite the absence of a pending patent. The confidentiality provisions of the 1962 Rules do not apply to Court of Appeals proceedings, and under the Intellectual Property Code, patent applications are published after 18 months, making confidentiality temporary rather than absolute.
• Revival Period: The denial of revival was proper. Section 113 of the 1962 Revised Rules of Practice requires revival within four months from the date of abandonment, a period that is mandatory and admits of no extension. Petitioner's revival petition, filed thirteen years after the September 20, 1988 abandonment date, was clearly out of time. Even under the subsequent Intellectual Property Code (Section 133.4), the period is only three months, underscoring the strict statutory limits.
• Negligence of Counsel: Schuartz v. Court of Appeals is controlling. The negligence of a patent applicant's counsel binds the client to prevent uncertainty in proceedings. Petitioner was inexcusably negligent: it waited eight years (from 1987 to 1995) to request a status update, and another four years (from 1996 to 2000) after learning of counsel's death and appointing new agents. The four-month period runs from the mailing of the abandonment notice, not from actual notice.
• Public Interest: Public interest and third-party rights weigh heavily against revival. Hypertension affects millions of Filipinos, and competition from Therapharma's Lifezar reduced prices by approximately 20% and increased accessibility. Granting revival would eliminate this competition and prejudice Therapharma's substantial good-faith investments. The patent system's purpose is to balance inventor protection with public benefit; strict compliance with procedural rules ensures that ideas enter the public domain when statutory protections are forfeited through negligence.
• Right of Priority: A right of priority under the Paris Convention does not equate to a patent grant. It merely confers preference in the grant of a patent when conflicting applications exist. Without an actual patent, the invention is not removed from the public domain in the Philippines.

• Substantial Compliance with Rule 45: The failure to attach all material portions of the record does not warrant automatic dismissal if the petitioner subsequently submits the required documents or if the attached documents sufficiently support the allegations to make out a prima facie case, provided the higher interest of justice is served by deciding the case on the merits. This doctrine applies the three guideposts: (1) only relevant and pertinent documents need be attached; (2) documents need not be duplicated if their contents appear in attached records; and (3) missing documents may be subsequently supplied.
• Negligence of Counsel in Patent Prosecution: The negligence of a patent applicant's resident agent or counsel binds the applicant. This doctrine, established in Schuartz v. Court of Appeals, ensures certainty in patent proceedings and prevents applicants from disowning counsel's conduct to circumvent procedural deadlines. Negligence is inexcusable when it could have been avoided through ordinary diligence, such as periodic status inquiries regarding pending applications.
• Intervention in Patent Appeals: While patent prosecution before the Intellectual Property Office is ex parte and confidential, once an appeal reaches the Court of Appeals, the Rules of Court govern, allowing intervention by parties with a legal interest in the outcome. The confidentiality of patent applications under the Intellectual Property Code is not absolute; applications must be published after 18 months from filing, after which interested parties may inspect the documents.
• Strict Construction of Patent Revival Periods: The statutory periods for revival of abandoned patent applications (four months under the 1962 Revised Rules of Practice, three months under the Intellectual Property Code) are mandatory and non-extendible. No equitable exceptions exist for delays caused by counsel's negligence or death.
• Public Interest in Pharmaceutical Patents: In determining whether to grant equitable relief in patent cases, courts must consider the public interest in access to affordable medicines, particularly for chronic conditions affecting large populations. The entry of generic competitors and the protection of third-party rights invested in good faith are significant factors weighing against the revival of abandoned applications that would restore monopoly pricing.

• "A patent is granted to provide rights and protection to the inventor after an invention is disclosed to the public. It also seeks to restrain and prevent unauthorized persons from unjustly profiting from a protected invention. However, ideas not covered by a patent are free for the public to use and exploit."
• "Negligence is inexcusable if its commission could have been avoided through ordinary diligence and prudence. It is also settled that negligence of counsel binds the client as this 'ensures against the resulting uncertainty and tentativeness of proceedings if clients were allowed to merely disown their counsels' conduct.'"
• "The right of priority given to a patent applicant is only relevant when there are two or more conflicting patent applications on the same invention. Because a right of priority does not automatically grant letters patent to an applicant, possession of a right of priority does not confer any property rights on the applicant in the absence of an actual patent."
• "Public interest will be prejudiced if, despite petitioner's inexcusable negligence, its Petition for Revival is granted... For the protection of public interest, Philippine Patent Application No. 35526 should be considered a forfeited patent application."

• Schuartz v. Court of Appeals, 390 Phil. 819 (2000) — Controlling precedent establishing that the negligence of a patent applicant's counsel binds the applicant, and that unreasonable delay in prosecuting patent applications constitutes laches and forfeiture of rights.
• Magsino v. De Ocampo, G.R. No. 166944, August 18, 2014 and Galvez v. Court of Appeals, 708 Phil. 9 (2013) — Established the three guideposts for determining substantial compliance with documentary requirements in petitions for review.
• Bernardo v. Court of Appeals, 341 Phil. 413 (1997) — Cited for the principle that a prudent party must maintain contact with counsel to monitor case progress, and cannot leave the fate of a case entirely to counsel without exercising due diligence.
• Creser Precision Systems, Inc. v. Court of Appeals, 349 Phil. 687 (1998) and Pearl and Dean v. Shoemart, Inc., 456 Phil. 474 (2003) — Articulated the balance between inventor protection and public domain access, emphasizing that no patent means no protection against copying.

• Rule 45, Section 4, Rules of Court — Requires petitions for review on certiorari to be accompanied by material portions of the record as would support the petition; subject to substantial compliance doctrine.
• Rule 19, Section 1, Rules of Court — Governs intervention in civil actions, allowing persons with legal interest in the matter to intervene at the court's discretion.
• Section 113, 1962 Revised Rules of Practice before the Philippines Patent Office in Patent Cases — Mandates that revival of abandoned applications must be filed within four months from the date of abandonment upon showing of unavoidable delay or excusable negligence.
• Section 133.4, Republic Act No. 8293 (Intellectual Property Code of the Philippines) — Provides a three-month period for revival of abandoned applications under the current law.
• Sections 44 and 45, Republic Act No. 8293 — Establish the publication requirement for patent applications after 18 months and the limited confidentiality of pending applications.
• Section 31, Republic Act No. 8293 — Defines the right of priority for patent applicants filing in convention countries.
• Section 34, Republic Act No. 165 (Patent Law) and Section 93, Republic Act No. 8293 — Provide for compulsory licensing of patents relating to food or medicine to prevent monopoly and ensure public access.

Mariano C. Del Castillo, Jose Catral Mendoza, Presbitero J. Velasco, Jr. (on leave), and Arturo D. Brion (on leave).